RT Journal Article
SR Electronic
T1 Management of HAM/TSP
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 49
OP 56
DO 10.1212/CPJ.0000000000000832
VO 11
IS 1
A1 Araujo, Abelardo
A1 Bangham, Charles R.M.
A1 Casseb, Jorge
A1 Gotuzzo, Eduardo
A1 Jacobson, Steve
A1 Martin, Fabiola
A1 Penalva de Oliveira, Augusto
A1 Puccioni-Sohler, Marzia
A1 Taylor, Graham P.
A1 Yamano, Yoshihisa
YR 2021
UL http://cp.neurology.org/content/11/1/49.abstract
AB Purpose of Review To provide an evidence-based approach to the use of therapies that are prescribed to improve the natural history of HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP)—a rare disease.Recent Findings All 41 articles on the clinical outcome of disease-modifying therapy for HAM/TSP were included in a systematic review by members of the International Retrovirology Association; we report here the consensus assessment and recommendations. The quality of available evidence is low, based for the most part on observational studies, with only 1 double-masked placebo-controlled randomized trial.Summary There is evidence to support the use of both high-dose pulsed methyl prednisolone for induction and low-dose (5 mg) oral prednisolone as maintenance therapy for progressive disease. There is no evidence to support the use of antiretroviral therapy. There is insufficient evidence to support the use of interferon-α as a first-line therapy.